BOUNDLESS BIO INC Stock Price, News & Analysis

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers, announced the departure of CFO Jami Rubin for personal reasons. The company does not plan to hire a successor CFO immediately. David Hinkle, Senior VP of Finance and Controller, will assume responsibility for Finance operations and the roles of principal financial and accounting officer.

CEO Zachary Hornby expressed gratitude for Rubin's contributions, particularly in the company's successful IPO and corporate strategy refinement. Rubin stated her pride in Boundless Bio's accomplishments and confidence in the company's future success, citing ongoing clinical trials for lead programs and a strong balance sheet to support their advancement.

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focusing on extrachromosomal DNA (ecDNA) biology, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's executives, Zachary Hornby (President and CEO) and Jami Rubin (CFO), will engage in a fireside chat session on Wednesday, September 18, 2024, at 10:20 a.m. ET in New York, NY.

Boundless Bio aims to develop transformative therapies for patients with previously intractable oncogene amplified cancers. Interested parties can access a live and archived webcast of the session through the 'Events & Presentations' section of the company's website under the Investors tab.

Boundless Bio (Nasdaq: BOLD) provided business updates and Q2 2024 financial results. Key points include:

1. BBI-355 POTENTIATE trial ongoing; initial proof-of-concept data now expected in H2 2025.
2. BBI-825 STARMAP trial ongoing; initial data expected in H2 2025.
3. ECHO ecDNA diagnostic validated for use in BBI-355 trial.
4. Operations streamlined to extend runway into Q4 2026.
5. Q2 2024 financials: Cash position $179.3M, R&D expenses $14.7M, G&A expenses $4.7M, Net loss $17.0M.

The company is focusing on core ecDTx programs while scaling back early discovery efforts. Enrollment in BBI-355 combination cohorts is slower than projected, prompting initiatives to accelerate recruitment.

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. President and CEO Zachary Hornby, along with CFO Jami Rubin, will represent the company in a fireside chat on June 12 at 3:20 p.m. ET in Miami, FL. The session will be available via live and archived webcast on the company’s website under the 'Events & Presentations' section.

Boundless Bio (Nasdaq: BOLD) reported their first quarter 2024 financial results, highlighting progress on their clinical trials. The company's Phase 1/2 POTENTIATE trial for BBI-355, a novel CHK1 inhibitor, and the Phase 1/2 STARMAP trial for BBI-825, a selective RNR inhibitor, have shown promising advancements. With a pro forma cash position of approximately $200 million following a $100 million IPO, Boundless Bio is well-positioned for future growth and development.

Boundless Bio (Nasdaq: BOLD) will be presenting at the Citizens JMP Life Sciences Conference 2024. The company's CFO will present on ecDNA biology therapies for oncogene amplified cancers. The webcast will be available on the company's website.